{"links":{"html":"https://www.erudio.com/reports/origami-2-nct06662786","json":"https://www.erudio.com/reports/origami-2-nct06662786.json","markdown":"https://www.erudio.com/reports/origami-2-nct06662786.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"origami-2-06662786"}},"request":"https://www.erudio.com/contact?report=origami-2-06662786"},"offer":{"cited_commentary_sources":20,"verified_hcp_statements":163,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI. For scientific and insight use inside the organization, not for promotional targeting or outreach. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":5,"optional":true,"price_per_verified_person_usd":15,"price_usd":75,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"origami-2-nct06662786"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=origami-2-06662786","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/origami-2-nct06662786","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-19T15:39:46.998176Z","notify_subscribers":false,"status":"new","summary":{"reason":"Initial accepted edition has no weekly change log.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":10,"no_commentary_found":2},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":0,"title":"Secondary endpoints"},{"claim_count":9,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":9,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":4,"title":"The comparison"},{"claim_count":4,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":3,"title":"Safety and tolerability"},{"claim_count":3,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":15,"coverage":"discussed","id":"A1","source_count":7,"title":"Interpretation of precursor evidence and expectations for validation"},{"claim_count":14,"coverage":"discussed","id":"A2","source_count":5,"title":"Resistance rationale, molecular selection and sequencing questions"},{"claim_count":20,"coverage":"discussed","id":"A3","source_count":5,"title":"Pretreatment molecular work-up and exploratory refinement beyond sidedness"},{"claim_count":5,"coverage":"discussed","id":"A4","source_count":4,"title":"Regional practice and consequences of first-line sequencing"},{"claim_count":4,"coverage":"discussed","id":"A5","source_count":1,"title":"Potential ctDNA hyperselection and equitable access"},{"claim_count":6,"coverage":"discussed","id":"A6","source_count":7,"title":"Enrollment discussion, referral and patient information"}],"counts":{"cited_sources":20,"claims_by_expression_type":{"comparison":12,"experience":8,"interpretation":30,"opinion":17,"question":3,"restatement":43,"uncertainty":3,"unspecified":47},"claims_by_kind":{"attributed_opinion":1,"interpretation":6,"limitation":1,"source_observation":155},"clinician_statements":77,"evidence_units":84,"findings":6,"people_cited":14,"people_identity_verified":5,"people_total":15,"screened_sources":24,"verified_claims":163},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":14,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":4,"views":7},"has_counterview":true,"limitations":3,"links":{"context":2,"support":22},"ma_question":true,"named_voices":9,"passages":12,"sources":7,"sources_by_kind":{"commentary":3,"media":4}},"title":"Enthusiasm supports further testing, not a conclusion of phase 3 superiority"},{"id":"F2","structure":{"claims":14,"claims_by_group":{"comparisons":4,"experience":1,"questions":0,"restated":7,"views":2},"has_counterview":false,"limitations":4,"links":{"context":4,"support":21},"ma_question":true,"named_voices":3,"passages":8,"sources":4,"sources_by_kind":{"media":4}},"title":"An active anti-EGFR benchmark coexists with regional practice variation"},{"id":"F3","structure":{"claims":16,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":6,"views":9},"has_counterview":false,"limitations":3,"links":{"context":6,"support":23},"ma_question":true,"named_voices":4,"passages":9,"sources":3,"sources_by_kind":{"media":3}},"title":"Correct molecular information must arrive before the first-line decision"},{"id":"F4","structure":{"claims":18,"claims_by_group":{"comparisons":1,"experience":1,"questions":1,"restated":8,"views":7},"has_counterview":true,"limitations":6,"links":{"context":2,"support":20},"ma_question":true,"named_voices":5,"passages":11,"sources":6,"sources_by_kind":{"commentary":1,"media":5}},"title":"Resistance biology motivates dual targeting; selection and sequencing remain questions"},{"id":"F5","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":1,"questions":0,"restated":3,"views":4},"has_counterview":false,"limitations":4,"links":{"context":1,"support":11},"ma_question":true,"named_voices":4,"passages":9,"sources":3,"sources_by_kind":{"commentary":1,"media":2}},"title":"Tolerability is a condition of the combination strategy, not a settled advantage"},{"id":"F6","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":6,"views":3},"has_counterview":false,"limitations":3,"links":{"context":3,"support":13},"ma_question":true,"named_voices":4,"passages":10,"sources":8,"sources_by_kind":{"commentary":4,"media":4}},"title":"Access concerns extend from ctDNA selection to trial referral and patient information"}],"medical_affairs_question":"What comparative benefit would justify replacing cetuximab, and which precursor signals do clinicians regard as sufficient only to support investigation or participation?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Enthusiasm supports investigation, not an OrigAMI-2 efficacy conclusion"},{"id":"section-2","level":2,"title":"An active comparator, regional alternatives and subgroup-specific guidance"},{"id":"section-3","level":2,"title":"Molecular work-up is a first-line decision issue, not merely a testing checklist"},{"id":"section-4","level":2,"title":"Dual targeting has a rationale; selection, alternatives and sequencing remain open"},{"id":"section-5","level":2,"title":"Tolerability and patient value are conditions for advancing the combination"},{"id":"section-6","level":2,"title":"Access determines whether selection and participation can be discussed equitably"},{"id":"section-7","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)"},{"findings":[],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":6},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":9},{"id":"F5","shared_claims":2}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F5","shared_claims":4}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F5","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-19T15:39:46.998176Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-19T15:48:54Z","record_hash":"d31497df77b486e588d25bd3c02fde27c6b07b343d8af61fe59b240fac73f058","release_hash":"3556367d9ca67a062558a627acee83cbb74a9d3d42ccae5ba09b47f184c17e4d","report_id":"erudio-nct06662786","run_id":"d7e0b674-09ac-4d1d-8b06-e8b901572950","schema_version":"5.0","slug":"origami-2-06662786","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Clinician commentary on OrigAMI-2 in the sources reviewed for this edition leads to one open question: What comparative benefit would justify replacing cetuximab, and which precursor signals do clinicians regard as sufficient only to support investigation or participation? Its leading findings: (1) enthusiasm supports further testing, not a conclusion of phase 3 superiority. (2) an active anti-EGFR benchmark coexists with regional practice variation. (3) correct molecular information must arrive before the first-line decision. 3 more findings follow. 20 of 24 screened sources are cited; not all HCPs or all public discussion.","meta_description":"24 sources screened · 163 verified statements (77 from speakers with a confirmed clinical role) from 20 sources · 6 findings. Updated Oct 19, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-19T15:48:54Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":24},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","Out of scope: 4 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.","72 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are not a representative sample of HCP opinion. Multiple audio and video versions repeat the same PeerView discussion.","Some passages on molecular selection, ctDNA, access and treatment choices were not fully assessed. A complete account of rare-mutation immunotherapy selection is also unavailable.","No protocol text or publication reporting results for NCT06662786 was available. The report therefore cannot independently appraise detailed methods or establish comparative efficacy or safety.","Regulatory information was incomplete. Speakers' references to lung-cancer use are development context, not an assessment of a colorectal-cancer indication.","Publication and posting dates do not necessarily identify the date of the underlying session or the first availability of its data.","Some speakers remain unidentified, and some named social-media authors lack confirmed clinical roles. Their statements cannot be used to infer additional verified HCP agreement.","Historical enrollment announcements do not establish current recruitment, access at a particular site or individual patient eligibility."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":2,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":9,"x_video":0,"youtube":7},"by_evidence_role":{"commentary":20},"count":20,"evidence_window":{"end":"2026-09-18","start":"2024-09-14"},"retrieval_snapshot":"2026-10-19T12:43:13.463861Z","timeline":[{"count":1,"week":"2024-W37"},{"count":1,"week":"2024-W44"},{"count":1,"week":"2025-W03"},{"count":1,"week":"2025-W05"},{"count":2,"week":"2025-W09"},{"count":1,"week":"2025-W13"},{"count":1,"week":"2025-W26"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W03"},{"count":1,"week":"2026-W07"},{"count":1,"week":"2026-W10"},{"count":1,"week":"2026-W17"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W31"},{"count":1,"week":"2026-W38"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06662786:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06662786:context","quote_policy":"short_quote_link_out"},{"id":"openfda:9e58b045-e352-4f62-99bf-77fae1bebc69:20260617","quote_policy":"short_quote_link_out"},{"id":"openfda:8bc6397e-4bd8-4d37-a007-a327e4da34d9:20260416","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-24v75vuozonrwvllcahtm7t5-3m3koir6lj22b","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-2fykzdsl6dmpn5q3u2ew3gkn-3lj6jcrxel22n","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:6949bb","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:7b7ee3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1533844499969069056:ec9876b0-67fb-4a30-b610-28ce435840f4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1548564300167450624:fb346f33-183b-4603-8d0d-4522ecefa506","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1806686501729923338:23e6ba84-dd26-4758-a595-66040bfc3920","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835020826040574420:20088e63-9029-4ef4-883f-5708c7fd3c42","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1880610487416819821:e5e9903e-9115-4bce-9b75-aa257a4fbf29","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1894363969395265597:9c4d60b9-f02b-4a95-917b-2531d34f3ebc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1905351532146778391:ce81e035-002a-40e5-ba22-f875eeac2c17","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2010143914506981745:911e03f6-c5b8-47f9-89fd-3f409ac723f4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2011205050623017045:4f362213-ad8b-4c4f-b641-49a3587ab813","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047511262565724173:08f741f2-5717-458c-b7e6-2da7e7cd2522","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050613997372936225:974105f8-e98d-4a2c-9470-ce46daa9a5bf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100957653392564335:fd1f4a03-2923-40a3-8f98-7227ecda790b","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:0j-fYKNUmYs","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:5TH-QyDmHmc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:94AnzPafFCc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:QALWmfdE7VQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:R0rexaM5ZCk","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:SrJI6cv4e6w","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:SsfzfZgRgGs","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Ul28psQyIEc","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":2,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":12,"x_video":0,"youtube":8},"by_evidence_role":{"commentary":24},"count":24,"evidence_window":{"end":"2026-09-18","start":"2022-06-06"},"retrieval_snapshot":"2026-10-19T12:43:13.463861Z","timeline":[{"count":1,"week":"2022-W23"},{"count":1,"week":"2022-W24"},{"count":1,"week":"2022-W28"},{"count":1,"week":"2024-W26"},{"count":1,"week":"2024-W37"},{"count":1,"week":"2024-W44"},{"count":1,"week":"2025-W03"},{"count":1,"week":"2025-W05"},{"count":2,"week":"2025-W09"},{"count":1,"week":"2025-W13"},{"count":1,"week":"2025-W26"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W03"},{"count":1,"week":"2026-W07"},{"count":1,"week":"2026-W10"},{"count":1,"week":"2026-W17"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W28"},{"count":2,"week":"2026-W31"},{"count":1,"week":"2026-W38"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Rybrevant"],"label":"amivantamab","slug":"amivantamab"},{"brand_names":["Erbitux"],"label":"cetuximab","slug":"cetuximab"},{"brand_names":["Adrucil","Favlyxa"],"label":"fluorouracil","slug":"fluorouracil"},{"reason":"Unmapped registry intervention: leucovorin calcium/levoleucovorin","status":"unmapped"},{"brand_names":["Eloxatin"],"label":"oxaliplatin","slug":"oxaliplatin"},{"brand_names":["Camptosar"],"label":"irinotecan","slug":"irinotecan"}],"indications":[{"reason":"Unmapped registry condition: Colorectal Neoplasms","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"OrigAMI-2","aliases":["OrigAMI-2","A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer"],"brief_title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Colorectal Neoplasms"],"enrollment":{"count":1000,"type":"ESTIMATED"},"interventions":[{"name":"Amivantamab","synonyms":["JNJ-61186372"],"type":"BIOLOGICAL"},{"name":"Cetuximab","synonyms":["Erbitux"],"type":"BIOLOGICAL"},{"name":"5-fluorouracil","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Leucovorin calcium/Levoleucovorin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Oxaliplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Irinotecan Hydrochloride","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06662786","official_title":"A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-12-15","type":"ESTIMATED"},"primary_endpoints":[{"description":"PFS is defined as the time from randomization until the date of objective disease progression or death (due to any cause), whichever comes first, as assessed by BICR using response evaluation criteria in solid tumors (RECIST) version (v) 1.1. Participants who have not progressed or have not died at the time of analysis will be censored at their last evaluable RECIST v1.1 assessment date.","measure":"Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to 4 years and 2 months"}],"registry_last_updated":"2026-09-25","registry_url":"https://clinicaltrials.gov/study/NCT06662786","short_name":"OrigAMI-2","short_name_basis":"registry_acronym","sponsor":"Janssen Research & Development, LLC","start_date":{"date":"2024-10-18","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"61186372COR3001","type":"sponsor_study_id"},{"domain":"EUCT number","id":"2024-513852-13-00","type":"registry"}],"study_type":"INTERVENTIONAL"}}}